Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

by Oryzon Genomics

Oryzon Genomics (ISIN Code: ES0167733015 , ORY ), a public clinical - stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced ...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream